Testosterone Enanthate Cardiovascular Impact Long-Term: What the Evidence Actually Shows

Why Cardiovascular Risk Is the Central Debate in Testosterone Therapy

Millions of men receive testosterone replacement therapy each year, and testosterone enanthate remains one of the most commonly prescribed formulations in the United States. The cardiovascular question has never been fully resolved by a single clean answer. That is partly because testosterone acts on the heart, vasculature, hematopoietic system, and lipid metabolism through several distinct mechanisms simultaneously.

Early observational data alarmed regulators. The FDA issued a safety communication in 2014 citing studies suggesting possible increased myocardial infarction risk, and in 2015 required a label update noting a possible association with cardiovascular events [1]. Those signals came largely from database analyses with significant confounding. Since then, two large prospective datasets, the T-Trials (NEJM, 2016) and the TRAVERSE RCT (NEJM, 2023), have sharpened the picture considerably.

What Makes Testosterone Enanthate Pharmacologically Distinct

Testosterone enanthate is an esterified form of testosterone dissolved in sesame oil. After intramuscular injection, ester hydrolysis releases free testosterone over 7 to 10 days, producing peak serum testosterone at 24 to 72 hours post-injection and a trough near day 10 to 14 [2]. This pharmacokinetic profile generates larger peak-to-trough swings than transdermal gels or subcutaneous pellets.

Those swings matter cardiovascularly. Supraphysiologic peaks, which can transiently push testosterone above 1,000 to 1,200 ng/dL after a 200 mg injection, may drive hematocrit and platelet aggregation effects more intensely than steady-state delivery systems. No head-to-head trial has compared TE injection against transdermal testosterone specifically for cardiovascular outcomes, but pharmacokinetic modeling predicts higher erythropoietic stimulation with injectable esters [3].

The Regulatory Timeline

• 2010: FDA approves testosterone products for classical hypogonadism only, not age-related decline.
• 2014: FDA issues Drug Safety Communication on possible cardiovascular risk [1].
• 2015: Label updated with cardiovascular warning; sponsors required to conduct a post-marketing trial.
• 2023: TRAVERSE results published; FDA reviewing implications for label language.

The T-Trials: Signal Detection in an Older Male Cohort

The Testosterone Trials (T-Trials) were a coordinated set of seven double-blind, placebo-controlled trials in 788 men aged 65 or older with a serum testosterone <275 ng/dL and at least one symptom of low testosterone [4]. The parent trial and its sub-studies were published in NEJM in 2016. Testosterone gel (1.62%, not enanthate) was used, but the mechanistic cardiovascular findings are the most cited data in the field and directly inform enanthate prescribing decisions.

Coronary Artery Plaque Findings

The cardiovascular sub-study (Atherosclerosis trial, N=170) used coronary CT angiography at baseline and 12 months. Testosterone-treated men showed a significantly greater increase in non-calcified coronary plaque volume compared with placebo: mean increase of 41 mm³ vs. 17 mm³ (P<0.001) [5]. Coronary artery calcium (CAC) score did not differ significantly between groups.

Non-calcified plaque is considered more vulnerable to rupture than calcified plaque, which makes this finding clinically relevant even without a documented MACE increase in the same cohort. The trial was not powered to detect differences in heart attack rates over 12 months; it was a surrogate endpoint study.

Sexual Function, Vitality, and Walking Distance

The primary T-Trials publications showed testosterone improved sexual desire and activity, vitality scores, and 6-minute walk distance [4]. These are the efficacy signals that drive prescribing. The cardiovascular concern sits alongside real symptomatic benefit, requiring a genuine risk-benefit calculation rather than a blanket prohibition.

Bone Density and Anemia Sub-Studies

Two additional T-Trials sub-studies showed significant increases in volumetric bone mineral density and corrected anemia in hypogonadal older men [6, 7]. These findings support testosterone's systemic anabolic and erythropoietic effects, which are biologically inseparable from the hematologic cardiovascular risks discussed below.

TRAVERSE: The Definitive MACE Trial

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy ResponSE) enrolled 5,246 men aged 45 to 80 years with hypogonadism (two morning testosterone measurements <300 ng/dL) plus either established cardiovascular disease or a high cardiovascular risk profile [8]. Participants received 1.62% testosterone gel (not enanthate, but the most directly applicable large-scale safety RCT) or placebo and were followed for a median of 33 months.

Primary Endpoint: MACE

The primary composite outcome was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. TRAVERSE showed testosterone was non-inferior to placebo: 7.0% vs. 7.3% (HR 0.96, 95% CI 0.83 to 1.12) [8]. This result largely satisfied the FDA's post-marketing requirement and shifted the clinical consensus toward "cardiovascular safety is acceptable in appropriately screened patients."

Atrial Fibrillation Signal

A pre-specified secondary endpoint showed atrial fibrillation occurred in 3.5% of the testosterone group vs. 2.4% placebo (HR 1.45, 95% CI 1.07 to 1.96, P = 0.02) [8]. This absolute difference of roughly 1.1 percentage points over 33 months is clinically meaningful in men who already have structural heart disease. The Endocrine Society's 2023 interim guidance notes that AF history is a risk factor warranting discussion before initiating testosterone therapy [9].

Pulmonary Embolism

Pulmonary embolism occurred in 0.9% testosterone vs. 0.5% placebo (HR 1.92, 95% CI 1.10 to 3.35) in TRAVERSE [8]. The absolute numbers were small, but the hazard ratio of nearly 2.0 reinforces the FDA's existing black-box warning about venous thromboembolism, particularly in men with inherited thrombophilias or prior VTE events.

Hematologic Effects: Polycythemia as the Dominant Vascular Mechanism

Testosterone stimulates erythropoietin secretion in the kidney and directly promotes erythroid progenitor differentiation in bone marrow [10]. For testosterone enanthate specifically, the injectable route produces higher erythropoietic stimulation per dose interval than transdermal preparations. Hematocrit rises are the most consistent cardiovascular signal across all testosterone formulations and delivery routes.

How Quickly Hematocrit Rises

In a 2017 meta-analysis of 51 randomized controlled trials (N=2,671), testosterone therapy raised hematocrit by a mean of 3.2 percentage points (95% CI 2.5 to 3.9) vs. Placebo [11]. Injectable formulations produced larger increases than transdermal. Time to peak effect is typically 3 to 6 months after initiating TE therapy.

A hematocrit exceeding 54% (Endocrine Society threshold for dose reduction or temporary discontinuation) occurs in approximately 7 to 11% of men on injectable testosterone in clinical practice series [12]. At that viscosity, whole-blood viscosity increases nonlinearly, raising theoretical risk of arterial and venous thrombosis.

Monitoring and Dose Adjustment

The Endocrine Society Clinical Practice Guideline (2018) recommends checking hematocrit at baseline, at 3 to 6 months, then annually [12]. If hematocrit exceeds 54%, the guideline advises dose reduction, extended dosing interval, or temporary cessation. Phlebotomy is sometimes used but is not formally endorsed by the guideline as a first-line strategy because it may raise iron deficiency without addressing the underlying stimulus.

For a man on 200 mg TE every 14 days who develops a hematocrit of 56%, a practical approach endorsed by many specialists is reducing to 150 mg every 14 days and rechecking at 6 weeks. If hematocrit remains elevated, switching to a transdermal formulation is preferable to indefinite phlebotomy.

VTE Risk Quantification

A nested case-control analysis in the UK Clinical Practice Research Datalink (N=19,215 testosterone users) found an odds ratio of 1.63 (95% CI 1.12 to 2.37) for VTE in the first 6 months of testosterone therapy [13]. The risk was highest in men with baseline hematocrit above 48% and in those receiving injectable esters vs. Topical formulations.

Lipid Effects: HDL Suppression and LDL Variability

HDL Cholesterol

HDL-C suppression is the most consistent lipid effect of testosterone therapy. Across RCTs, testosterone reduces HDL-C by approximately 5 to 10% from baseline [14]. Supraphysiologic peaks from injectable testosterone enanthate may suppress HDL more than physiologically dosed transdermal preparations, though head-to-head lipid data are sparse.

The mechanism involves upregulation of hepatic lipase, which accelerates HDL catabolism. HDL particles become smaller and denser on testosterone, with uncertain functional implications for reverse cholesterol transport efficiency.

LDL Cholesterol and Total Cholesterol

LDL-C changes with physiologic testosterone replacement are typically modest and in some trials are neutral or slightly favorable [14, 15]. A 2020 systematic review and meta-analysis (52 RCTs, N=3,431) found no statistically significant change in LDL-C with testosterone therapy (mean difference: -0.07 mmol/L, 95% CI -0.18 to 0.04) [15]. Total cholesterol fell slightly, consistent with the HDL reduction driving most of the net change.

Triglycerides

Testosterone tends to reduce fasting triglycerides modestly in hypogonadal men, possibly by improving insulin sensitivity and hepatic lipid clearance [15]. In a man with hypogonadism and metabolic syndrome, this effect can be clinically useful, though it does not offset HDL reduction for global cardiovascular risk scoring purposes.

Clinical Lipid Monitoring

The American Association of Clinical Endocrinology recommends obtaining a fasting lipid panel before initiating testosterone therapy and repeating it at 6 to 12 months [16]. If LDL-C rises above 190 mg/dL or the patient's calculated 10-year ASCVD risk increases meaningfully, statin initiation or intensification should follow standard ACC/AHA cholesterol guidelines rather than testosterone discontinuation as a primary lipid strategy.

Blood Pressure and Left Ventricular Effects

Blood Pressure

Testosterone has no consistent effect on systolic or diastolic blood pressure in physiologic replacement ranges across the largest RCTs, including TRAVERSE [8]. Supraphysiologic doses used in performance-enhancement contexts (beyond the scope of this clinical review) are a different matter, but at standard hypogonadism treatment doses (100 to 200 mg TE every 7 to 14 days), blood pressure effects appear neutral [17].

Left Ventricular Hypertrophy

Observational data in men using testosterone for bodybuilding purposes show elevated rates of concentric left ventricular hypertrophy and reduced LV systolic function, but these populations use doses 5 to 10 times higher than prescribed replacement doses [18]. Within the therapeutic range, no RCT has documented significant LV mass index increases attributable to testosterone over 12 to 36 months.

A 2016 echocardiographic sub-study from the T-Trials (N=62) found no significant change in LV mass, LV ejection fraction, or diastolic function parameters after 12 months of testosterone vs. Placebo [19]. This was a small sample with limited statistical power, but it is the best controlled data available for physiologic replacement doses.

Endothelial Function and Coronary Vasodilation

Testosterone has direct vasodilatory effects on coronary arteries, mediated partly through calcium channel inhibition and partly through androgen receptor-dependent nitric oxide pathways [20]. Short-term intracoronary testosterone infusion studies in men with established coronary artery disease produced dose-dependent dilation and improved exercise-induced ischemia on nuclear perfusion imaging.

These acute vasodilatory effects do not necessarily translate into long-term atheroprotection, as the T-Trials plaque data illustrate. The mechanistic tension between acute vasodilation and chronic plaque progression remains one of the genuinely unresolved questions in testosterone cardiovascular pharmacology.

A 2019 Cochrane systematic review of testosterone therapy and cardiovascular risk (44 RCTs, N=8,119) found no significant increase in cardiovascular mortality, myocardial infarction, or stroke, but noted that trials were generally of short duration and inadequate statistical power to detect rare events [21]. TRAVERSE addressed that power gap directly.

Risk Stratification Before Prescribing Testosterone Enanthate

Not every hypogonadal man carries the same cardiovascular risk profile, and the prescribing decision for testosterone enanthate should be individualized using a structured approach.

Men Who Are Generally Appropriate Candidates

• Age <65 with symptomatic hypogonadism and no known cardiovascular disease
• Total testosterone confirmed <300 ng/dL on two morning samples [12]
• Baseline hematocrit <48%, no prior VTE, no untreated severe sleep apnea
• Baseline 10-year ASCVD risk <10% by pooled cohort equations [22]

Men Requiring Enhanced Screening or Alternative Approaches

• Prior MI, stroke, or established CAD: TRAVERSE supports cautious use with monitoring, but the AF and PE signals require discussion [8]
• Baseline hematocrit 48 to 53%: transdermal delivery preferred over injectable TE to minimize erythropoietic stimulus [12]
• Prior VTE or known thrombophilia: FDA black-box warning applies; consultation with hematology before initiating [1]
• Severe, untreated obstructive sleep apnea: testosterone worsens OSA and indirectly increases cardiovascular risk through nocturnal hypoxemia [12]
• Active heart failure with reduced ejection fraction: insufficient RCT data; the 2023 ACC/AHA heart failure guideline does not endorse testosterone for this population [23]

The Monitoring Schedule That Guidelines Support

Per the Endocrine Society 2018 Clinical Practice Guideline, the recommended monitoring schedule after initiating testosterone enanthate is [12]:

• 3 to 6 months: Serum testosterone (trough for IM injections), hematocrit, PSA, symptom assessment
• 12 months: Repeat all above plus fasting lipids, blood pressure
• Annually thereafter: All of the above; bone density at 1 to 2 years if baseline osteopenia was present

The Endocrine Society guideline states directly: "We suggest measuring hematocrit before initiating testosterone therapy, at 3 to 6 months after initiation, and then annually" [12].

What Prescribers Often Miss: The Injection Timing Effect on Hematocrit

One under-discussed clinical point is that splitting a biweekly 200 mg TE dose into two weekly 100 mg injections reduces peak testosterone exposure by approximately 30 to 40% while maintaining equivalent mean weekly testosterone area under the curve [3]. Lower peaks mean less erythropoietic spike. For men who develop hematocrit in the 50 to 53% range on 200 mg every two weeks, switching to 100 mg every week is a lower-risk intervention than dose reduction alone and may better sustain symptom control.

This is particularly relevant for men in their 50s with borderline cardiovascular risk who need reliable testosterone delivery but whose hematocrit trends upward with standard biweekly dosing.

Current Guideline Positions: Where the Major Societies Stand

The Endocrine Society (2018) supports testosterone therapy for men with classical hypogonadism and documented low testosterone but recommends against initiating therapy in men who have had a cardiovascular event within the prior 6 months [12].

The American Urological Association (2018) echoes this position and adds that testosterone should not be initiated in men with a recent stroke or unstable angina [24].

The American College of Cardiology has not issued a standalone testosterone cardiovascular guideline but has published expert consensus in the Journal of the American College of Cardiology noting that "current evidence does not support withholding testosterone therapy from otherwise eligible patients based solely on cardiovascular risk, provided that monitoring protocols are followed" [25].

The 2023 TRAVERSE publication prompted updated clinical recommendations from several academic medical centers to remove blanket cardiovascular contraindications for men with stable CAD, replacing them with structured shared decision-making documentation and the monitoring protocol described above.